Format

Send to

Choose Destination
Indian J Sex Transm Dis AIDS. 2018 Jan-Jun;39(1):1-6. doi: 10.4103/ijstd.IJSTD_99_17.

A meta-analysis on efficacy and tolerability of sildenafil for erectile dysfunction in patients with diabetes mellitus.

Author information

1
Department of Pharmacology, Medical College, Vadodara, Gujarat, India.

Abstract

Erectile dysfunction (ED) is a common complication in patients with diabetes mellitus (DM). Sildenafil, a phosphodiesterase-5 inhibitor, is commonly used in patients with ED. This meta-analysis was planned to determine the strength of evidence to assess the efficacy and tolerability of sildenafil in patients with DM-associated ED. Electronic searches were carried out to identify randomized controlled trials (RCTs) which reported clinical efficacy of sildenafil in patients with DM-associated ED. Data were extracted and methodological quality was assessed. Relative Risk (RR) with 95% confidence intervals (CIs) was estimated for the dichotomous outcomes, and the mean difference with 95% CI was estimated for continuous data. Eight randomized controlled trials (RCTs) involving 1172 patients met with our inclusion criteria. In comparison to placebo, sildenafil significantly improved the overall sexual performance in patients of ED associated with DM with relative risk (RR) of answering "yes" to global efficiency question being 3.99 (95% CI: 2.58-6.18) compared to placebo. The rate of discontinuation due to treatment-related adverse reactions was 2.4% in sildenafil arm with RR of 2.67 (95% CI: 0.74-9.62). Sildenafil is an effective and safe medication for the treatment of ED associated with DM.

KEYWORDS:

Diabetes mellitus; erectile dysfunction; sildenafil

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center